Category: Ageusia

Cognitive dysfunction in post-COVID-19 condition: Mechanisms, management, and rehabilitation

Posted on | Posted on John Murphy | Leave a Comment on Cognitive dysfunction in post-COVID-19 condition: Mechanisms, management, and rehabilitation

Marika Möller, Kristian Borg, Christer Janson, Maria Lerm, Johan Normark, Katarina NiwardSeptember 2023, Journal of Internal MedicineVolume 294, Issue 5 p. 563-581 Abstract The long-term effects of COVID-19 on cognitive function have become an area of increasing concern. This paper provides an overview of characteristics, risk factors, possible mechanisms, and management strategies for cognitive dysfunction in post-COVID-19 condition (PCC). Prolonged cognitive […]

Alteration of the blood-brain barrier by COVID-19 and its implication in the permeation of drugs into the brain

Posted on | Posted on John Murphy | Leave a Comment on Alteration of the blood-brain barrier by COVID-19 and its implication in the permeation of drugs into the brain

Héctor Hernández-Parra1,2 Octavio Daniel Reyes-Hernández3 Gabriela Figueroa-González4 Manuel González-Del Carmen5 Maykel González-Torres6 Sheila I. Peña-Corona2 Benjamín Florán7 Hernán Cortés8* Gerardo Leyva-Gómez2* https://pubmed.ncbi.nlm.nih.gov/36998270/ Diverse neurological symptoms have been reported in patients with SARS-CoV-2 disease (COVID-19), including stroke, ataxia, meningitis, encephalitis, and cognitive impairment. These alterations can cause serious sequelae or death and are associated with the entry of SARS-CoV-2 into the Central Nervous System […]

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside

Posted on | Posted on John Murphy | Leave a Comment on COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside

David Sulzer, Angelo Antonini, Valentina Leta, Anna Nordvig, Richard J. Smeyne, James E. Goldman, Osama Al-Dalahmah, Luigi Zecca, Alessandro Sette, Luigi Bubacco, Olimpia Meucci, Elena Moro, Ashley S. Harms, Yaqian Xu, Stanley Fahn & K. Ray Chaudhuri  npj Parkinson’s Disease volume 6, Article number: 18 (2020) Cite this article Abstract This Viewpoint discusses insights from basic science and clinical perspectives on coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the brain, with a particular focus […]

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside

Posted on | Posted on John Murphy | Leave a Comment on COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside

npj Parkinson’s Disease volume 6, Article number: 18 (2020) Cite this article Abstract This Viewpoint discusses insights from basic science and clinical perspectives on coronavirus disease 2019 (COVID-19)/severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection in the brain, with a particular focus on Parkinson’s disease. Major points include that neuropathology studies have not answered the central issue of whether the virus enters central […]

Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review

Posted on | Posted on John Murphy | Leave a Comment on Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review

Authors: Elnaz Khani,aSajad Khiali,aSamineh Beheshtirouy,a and Taher Entezari-Malekia,b,∗ Eur J Pharmacol. 2021 Dec 5; 912: 174582.Published online 2021 Oct 19. doi:  10.1016/ j.ejphar.2021.174582 PMCID: PMC8524700PMID: 34678243 Abstract The acute loss of taste and smell following COVID-19 are hallmark symptoms that affect 20–85% of patients. However, the pathophysiology and potential treatments of COVID-19 smell and taste loss are not fully understood. We […]

Smell and Taste Loss Recovery Time in COVID-19 Patients and Disease Severity

Posted on | Posted on John Murphy | Leave a Comment on Smell and Taste Loss Recovery Time in COVID-19 Patients and Disease Severity

Authors: Athanasia Printza,1,*Mihalis Katotomichelakis,2Konstantinos Valsamidis,1Symeon Metallidis,3Periklis Panagopoulos,4Maria Panopoulou,5Vasilis Petrakis,4 and Jannis Constantinidis1 J Clin Med. 2021 Mar; 10(5): 966.Published online 2021 Mar 2. doi: 10.3390/jcm10050966 PMCID: PMC7957474PMID: 33801170 Abstract A significant proportion of people infected with SARS-CoV-2 report a new onset of smell or taste loss. The duration of the chemosensory impairment and predictive factors of recovery are still unclear. We aimed […]

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

Posted on | Posted on John Murphy | Leave a Comment on Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

Authors: Yapeng Su 28, Dan Yuan 28, Daniel G. Chen 28,Mark M. Davis, Jason D. Goldman, James R. Heath 29 Highlights Longitudinal multiomics associate PASC with autoantibodies, viremia and comorbidities Reactivation of latent viruses during initial infection may contribute to PASC Subclinical autoantibodies negatively correlate with anti-SARS-CoV-2 antibodies Gastrointestinal PASC uniquely present with post-acute expansion of cytotoxic T cells […]

Covid-19 Vaccine Analysis: The most common adverse events reported so far

Posted on | Posted on John Murphy | Leave a Comment on Covid-19 Vaccine Analysis: The most common adverse events reported so far

Authors: DATED: AUGUST 6, 2021 BY SHARYL ATTKISSON  As of July 19, 2021 there were 419,513 adverse event reports associated with Covid-19 vaccination in the U.S., with a total of 1,814,326 symptoms reported. That’s according to the federal Vaccine Adverse Event Reporting System (VAERS) database. Report an adverse event after vaccination online here. Each symptom reported does […]

Prevalence of anosmia and ageusia symptoms among long-term effects of COVID-19.

Posted on | Posted on John Murphy | Leave a Comment on Prevalence of anosmia and ageusia symptoms among long-term effects of COVID-19.

Authors: Moraschini V1, Reis D1, Sacco R2, Calasans-Maia MD3 COVID‐19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) that currently presents the greatest, most challenging health concern worldwide. Since the first reports of the disease in December 2019, clinicians and scientists have endeavored to understand the main symptoms, risk factors, and prognosis of […]

Age-dependent appearance of SARS-CoV-2 entry sites in mouse chemosensory systems reflects COVID-19 anosmia-ageusia symptoms

Posted on | Posted on John Murphy | Leave a Comment on Age-dependent appearance of SARS-CoV-2 entry sites in mouse chemosensory systems reflects COVID-19 anosmia-ageusia symptoms

Authors: Julien Brechbühl,Ana Catarina Lopes,Dean Wood,Sofiane Bouteiller,Aurélie de Vallière,Chantal Verdumo, and Marie-Christine Broillet Abstract COVID-19 pandemic has given rise to a collective scientific effort to study its viral causing agent SARS-CoV-2. Research is focusing in particular on its infection mechanisms and on the associated-disease symptoms. Interestingly, this environmental pathogen directly affects the human chemosensory systems leading to […]